WO2005030985A2 - Utilisation de sequences d'acides amines impliquees dans l'elongation d'acides gras lors de l'identification et/ou du developpement de composes destines a prevenir et/ou a traiter des maladies metaboliques - Google Patents

Utilisation de sequences d'acides amines impliquees dans l'elongation d'acides gras lors de l'identification et/ou du developpement de composes destines a prevenir et/ou a traiter des maladies metaboliques Download PDF

Info

Publication number
WO2005030985A2
WO2005030985A2 PCT/GB2004/004103 GB2004004103W WO2005030985A2 WO 2005030985 A2 WO2005030985 A2 WO 2005030985A2 GB 2004004103 W GB2004004103 W GB 2004004103W WO 2005030985 A2 WO2005030985 A2 WO 2005030985A2
Authority
WO
WIPO (PCT)
Prior art keywords
coa
amino acid
involved
fatty acids
acid sequence
Prior art date
Application number
PCT/GB2004/004103
Other languages
English (en)
Other versions
WO2005030985A3 (fr
Inventor
Gert Jules Hector De Wilde
Michael John Scott Saunders
Original Assignee
Devgen N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322493A external-priority patent/GB0322493D0/en
Application filed by Devgen N.V. filed Critical Devgen N.V.
Publication of WO2005030985A2 publication Critical patent/WO2005030985A2/fr
Publication of WO2005030985A3 publication Critical patent/WO2005030985A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • the present invention relates to methods for the identification and/or the development of compounds that can be used to prevent and/or to treat metabolic diseases, and to the use of amino acid sequences that are involved in the elongation of fatty acids in such methods.
  • the invention also relates to compounds that have been identified and/or developed using said methods, to pharmaceutical compositions that contain such compounds, and to the use of said compounds in the preparation of pharmaceutical compositions, in particular of pharmaceutical compositions for the prevention and/or treatment of metabolic diseases.
  • the invention further relates to compounds that can interact with amino acid sequences that are involved in the elongation of fatty acids, to pharmaceutical compositions that contain such compounds, and to the use of said compounds in the preparation of pharmaceutical compositions, in particular of pharmaceutical compositions for the prevention and/or treatment of metabolic diseases.
  • fatty acids are generally synthesized de novo from acetyl-CoA and stearyl-CoA through a series of reactions mediated by acetyl-CoA carboxylase (also referred to as "ACC) and fatty acid synthase (also referred to as "FAS").
  • ACC acetyl-CoA carboxylase
  • FOS fatty acid synthase
  • the fatty acid palmitic acid (which, in accordance with standard fatty acid nomenclature, is often designated as "16:0", in which "16” denotes the number of carbon atoms in the fatty acid carbon chain - i.e. C ⁇ 6 - and "0" denotes the number of unsaturated bonds, i.e. 0), see again Moon et al., supra. This is released into the cytosol, from where it is either further elongated - i.e. to stearic acid (18:0, which is the main saturated product resulting from the elongation reaction) and/or is desaturated (e.g.
  • the elongation of fatty acids is performed in the mitochondria and more commonly in the endoplasmatic reticulum by a complex of multiple enzymes, and involves a cycle of condensation (referred to herein as the “First Step"), reduction (referred to herein as the “Second Step”), dehydration (referred to herein as the “Third Step”) and reduction (referred to herein as the “Fourth Step”), which are as follows (see Moon and Horton, supra):
  • Second Step condensation between a fatty acyl-CoA and malonyl-CoA to form 3- ketoacyl-CoA
  • Second Step reduction of the 3-ketoacyl-CoA using NADPH to form 3-hydroxyacyl- CoA;
  • This cycle results in the addition of two carbon atoms to the fatty acid chain, compared to the starting fatty acid.
  • the fatty acid chain thus elongated may then either be further elongated through another cycle of condensation, reduction, dehydration and reduction; and/or may be desaturated.
  • the further elongated and/or desaturated fatty acids thus obtained may then again be further elongated and/or desaturated.
  • palmitic acid as the main product from the de novo synthesis by the FASIACC system
  • a whole range of saturated and unsaturated fatty acids maybe synthesized.
  • some families of biologically important fatty acids cannot be synthesized by animals, because they lack some of the required enzymes.
  • animals when it comes to the desaturation of saturated fatty acids and/or the further desaturation of unsaturated fatty acids, animals lack the desaturases required for introducing a double bond beyond the 9 th position in the carbon chain, and can only insert additional double bonds between an existing double bond and the terminal carboxylgroup.
  • animals cannot synthesize (the precursors for) the fatty acids of the so-called “(n-6) series” (in which, in accordance with standard biochemical nomenclature, "n” denotes the number of carbon atoms and “6” denotes the position of the last double bond, counting from the methyl group determining the metabolic family) and the "(n-3) series", which include for example linoleic acid (18:2(n-6)), the primary precursor for arachidonic acid (20:4 (n-6)) and other fatty acids of the (n-6) series, and « p z ⁇ -linolenic acid (18:3(n-3)), the main precursor for fatty acids of the (n-3) series.
  • such assays may also be performed with for example microsomal preparations, which may contain two or more or essentially all enzymes involved in the First Step to Fourth Step above, so as to measure the activity of the entire pathway, or the influence of a single enzyme on said pathway.
  • ELO1, ELO2 and or ELO3 cerevisiae that lacks one or more of the native elongations enzymes ELO1, ELO2 and or ELO3 (see Toke et al. and Oh et al., both supra).
  • the nucleotide sequences and proposed amino acid sequences for the human condensation enzymes involved in the First Step above - which are also collectively referred to as the "ELOVL" family - have also been described in the art, i.e.
  • - ELOVL6 which is the human ortholog of the mouse elongase LCE, which has specificity for the conversion of C 1 and Ci 6 saturated and mono-unsaturated fatty acids, such as for the conversion of C ⁇ 6 to C t s fatty acids, and in particular for the conversion of palmitic acid (16:0) to stearic acid (18:0).
  • the nucleotide sequence of ELOVL6 is given in SEQ ID NO: 1 (mRNA sequence) and SEQ ID NO: 2 (mRNA - coding sequence); the amino acid sequence is given in SEQ ID NO: 3.
  • ELOVL3 which is the human ortholog of the mouse elongase Cig30 and the S. cerevisiae elongase ELO2, with specificity for very long chain fatty acids (up to C 26 ).
  • the nucleotide sequence of ELOVL3 is given in SEQ ID NO: 6 (mRNA sequence) and SEQ ID NO: 7 (mRNA - coding sequence); the amino acid sequence is given in SEQ ID NO:8. See also Genkbank accession numbers NM_152310 (gi 23097309); nucleotide sequence) and NP_689523.1 (gi 23097310; amino acid sequence). Reference is also made to Tvrdik (1997), supra, and to Moon et al., supra.
  • ELOVL5 also called “HELO 1"
  • HELO 1 polyunsaturated fatty acids
  • the nucleotide sequence of ELOVL5 is given in SEQ ID NO: 9 (mRNA sequence) and SEQ ID NO: 10 (mRNA - coding sequence); the amino acid sequence is given in SEQ ID NO:l 1. See also Genkbank accession numbers NM_021814 (gi 21361903) for the nucleotide sequence and NP_068586.1 (gi 11464975) for the amino acid sequence, amino acid sequence). Reference is also made to Leonard et al., supra.;
  • ELOVL4 which is involved in the elongation of very long chain fatty acids.
  • the nucleotide sequence of ELOVL5 is given in SEQ ID NO: 12 (mRNA sequence) and SEQ ID NO: 13 (mRNA - coding sequence); the amino acid sequence is given in SEQ ID NO : 14. See also Genkbank accession numbers NM_022726 (gi 21362099) for the nucleotide sequence andNP_073563.1 (gi 12232379) for the amino acid sequence.
  • ELOVL2 which is the human ortholog of the mouse elongase Ssc2, which has been shown to accept arachidonic acid and eicosapentaneoic acid as its substrates.
  • the nucleotide sequence of ELOVL2 is given in SEQ ID NO: 15 (mRNA sequence) and SEQ ID NO: 16 (mRNA - coding sequence); the amino acid sequence is given in SEQ ID NO: 17. See also Genkbank accession numbers NM_17770 (gi 8923311) for the nucleotide sequence and NP_060240.1 (gi 8923312) for the amino acid sequence. Reference is also made to Tvirdik (2000), supra, and to Moon et al., supra.
  • ELOVL1 which is the human ortholog of the mouse elongase Sscl and the S. cerevisiae elongase ELO 3, with specificity for very long chain fatty acids.
  • the nucleotide sequence of ELOVL1 is given in SEQ ID NO: 18 (mRNA sequence) and SEQ ID NO: 19 (mRNA - coding sequence); the amino acid sequence is given in SEQ ID NO:20. See also Genkbank accession numbers NM_22821 (gi 13489092) for the nucleotide sequence andNP_073732.1 (gi 13489093) for the amino acid sequence. Reference is also made to Tvirdi (2000), supra, and to Moon et al., supra.
  • condensation enzymes described above contain a histidine-rich motif (FL ⁇ H), and also contain an ELO-domain (as determined by SMARTTM analysis (see http://smai-t.embl-heidclbcre.de/) and/or PFAM protein searchTM (see for example http://pfam.wustl.edu/).
  • ELO domain in the amino acid sequence of SEQ ID NO: 3 comprises amino acids 10-265.
  • bio-informatic analysis has also identified a further human amino acid sequence - shown in SEQ ID NO: 5 - that contains both an FL ⁇ HH motif (amino acids 24-28) as well as an "ELO" domain on PFAM protein searchTM (amino acids 1-94).
  • this amino acid sequence is also involved in the elongation of fatty acids, and in particular in the condensation between a fatty acyl-CoA and malonyl-CoA to form 3-ketoacyl-CoA (i.e. the First Step above).
  • nucleotide sequence for this hypothetical protein is given in SEQ ID NO: 4 and the amino acid sequence is given in SEQ ID NO: 5.
  • Genbank accession number AL137506 gi: 6808153
  • CAB 70777.1 gi: 6808154
  • KAR 3-ketoacyl-CoA reductase
  • SEQ ID NO: 21 mRNA sequence
  • SEQ ID NO: 22 mRNA - coding sequence
  • amino acid sequence is given in SEQ ID NO: 23. See also Genkbank accession numbers NM_016142 (gi 7705854) for the nucleotide sequence andNP_057226.1 (gi 7705855) for the amino acid sequence.
  • KAR has also been described in the art under the name "17-beta- hydroxysteroid dehydrogenase” of "HSD17BI2 "; - "trans-2,3-enoyl-CoA reductase” or "TER”, which is involved in the reduction of trans-2,3-enoyl-CoA to saturated acyl-CoA (the Fourth Step above).
  • the nucleotide sequence of TER is given in SEQ ID NO: 24 (mRNA sequence) and SEQ ID NO: 25 (mRNA - coding sequence); the amino acid sequence is given in SEQ ID NO: 26.
  • TER contains a " steroid _short” domain, again as determined by PFAM analysis, (amino acid residues 12-157).
  • fatty acid desaturases enzymes which are refened to as "fatty acid desaturases” .
  • SCD V the enzymes known as the "stearoyl-CoA-desaturases” or "SCD V.
  • SCD's are SCD-1 and SCD-5 from humans, which are inter alia described in the International applications WO 01/66758 and WO 02/26944, respectively. Reference is also made to Ntambi et al., Cun. Opin.
  • amino acids involved in the elongation of fatty acids can be used as targets (as described herein) in the field of metabolic disease.
  • amino acid sequences that are involved in one of the four steps of the elongation cycle of fatty acids - i.e. the First Step, Second Step, Third Step and Fourth Step as described above - can be used as targets in metabolic disease, as further described hereinbelow.
  • amino acid sequence is defined to include any peptide, polypeptide, protein or enzyme.
  • the amino acid sequence that is used in the invention is derived from multicellular animals, in particular from vertebrate animals, more in particular mammals, and even more in particular from humans, as further described hereinbelow.
  • the amino acid sequence that is used in the invention is chosen from the elongases, as described above, and more in particular in the elongases that are involved in the First Step, Second Step and/or Third Step above.
  • the amino acid sequence used in the invention is chosen from elongases involved in the First Step above, i.e. from the condensation enzymes involved in the condensation between a fatty acyl-CoA and malonyl-CoA to form 3-ketoacyl-CoA.
  • the amino acid sequence used in the invention is chosen from condensation enzymes involved in the First Step above that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for fatty acids with a length of the carbon chain of 24 carbon atoms or less (such as palmitic acid, stearic acid, linoleic acid and/or linolenic acid), compared to fatty acids with a length of the carbon chain of more than 24 carbon atoms.
  • a suitable assay such as one of the assays mentioned hereinabove
  • the amino acid sequence used in the invention is chosen from condensation enzymes involved in the First Step above that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for fatty acids with a length of the carbon chain of 20 carbon atoms or less (such as palmitic acid, stearic acid, linoleic acid and/or linolenic acid), compared to fatty acids with a length of the carbon chain of more than 20 carbon atoms.
  • condensation enzymes involved in the First Step above that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for fatty acids with a length of the carbon chain of 20 carbon atoms or less (such as palmitic acid, stearic acid, linoleic acid and/or linolenic acid), compared to fatty acids with a length of the carbon chain of more than 20 carbon atoms.
  • the amino acid sequence used in the invention is chosen from condensation enzymes involved in the First Step above that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for fatty acids with a length of the carbon chain of 18 carbon atoms or less, compared to fatty acids with a length of the carbon chain of more than 18 carbon atoms; and specifically for fatty acids w ⁇ th a length of the carbon chain of 16 or 18 carbon atoms, compared to fatty acids with a length of the carbon chain of more than 18 carbon atoms
  • the amino acid sequence used in the invention is chosen from condensation enzymes involved in the First Step above that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for fatty acids with a length of the carbon chain of 16 carbon atoms, compared to fatty acids with a length of the carbon chain of more than 16 carbon
  • the "substrate specificity" or “specificity” of an elongase can be determined using a suitable assay in a manner known per se, as will be clear to the skilled person. Generally, this will involve comparing two relevant substrates in such an assay, and determining which substrate is better accepted (e.g. more easily and/or faster converted) by the enzyme involved.
  • the substrates may be tested in one of the in vivo or in vitro assays mentioned above and/or hereinbelow.
  • the substrate specificity can be determined/expressed by means of the "turnover" of the substrate(s) involved (i.e. the amount of substrate converted by the enzyme within a given period of time, usually measured at a pre-determined concentration), with a higher turnover of a first substrate compared to a second substrate being an indication that the first substrate is better accepted by the enzyme involved than the second substrate.
  • the substrate specificity can be expressed using the well-known K m value, with a lower K m value of a first substrate compared a second substrate being an indication that the first substrate is better accepted by the enzyme involved than the second substrate.
  • an enzyme is considered to have "specificity" for a first substrate compared to a second substrate if, in a suitable assay, either (1) the turnover of the first substrate is at least 1.1 times, preferably at least 1.5 times, more preferably at least 2.5 times, even more preferably at least 5 times, and in particular 10 times or more the turnover for the second substrate (as measured in the same assay using essentially the same conditions; and/or (2) the K m value of the first substrate is less than 90%, preferably less than 50%, more preferably less than 25%, even more preferably less than 10% of the K m value for the second substrate (as measured in the same assay using essentially the same conditions).
  • the use of an amino acid sequence that is involved in - e.g. has specificity for - the elongation of unsaturated fatty acids that cannot be synthesized de novo by animals, or that are derived from fatty acid precursors that cannot be synthesized de novo by animals (i.e. by elongation and/or further desaturation), is less prefened.
  • the use of amino acid sequence(s) that are involved in the elongation of unsaturated fatty acids of the (n-3) family or (n-6) family are less prefened.
  • amino acid sequence(s) that are involved in the elongation of unsaturated fatty acids of the (n-3) family or (n-6) family with a length of the carbon chain of less than 20 carbon atoms are less prefened.
  • the amino acid sequence(s) used as targets in the invention is/are chosen from condensation enzymes involved in the First Step above that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for saturated fatty acids compared to unsaturated fatty acids of the (n-3) family and/or (n-6) family.
  • the amino acid sequence used in the invention is chosen from condensation enzymes involved in the First Step above that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for saturated fatty acids with 24 carbon atoms or less in the fatty acid chain (such as palmitic acid and stearic acid), compared to both (1) saturated and unsaturated fatty acids with more than 24 carbon atoms in the fatty acid chain; as well as (2) unsaturated fatty acids of the (n-3) family and/or (n-6) family with 20 carbon atoms or less in the fatty acid chain (such as linoleic acid and alpha-linolenic acid).
  • a suitable assay such as one of the assays mentioned hereinabove
  • the amino acid sequence used in the invention is chosen from condensation enzymes involved in the First Step above that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for saturated fatty acids with 20 carbon atoms or less in the fatty acid chain (such as palmitic acid and stearic acid), compared to both (1) saturated and unsaturated fatty acids with more than 20 carbon atoms in the fatty acid chain; as well as (2) unsaturated fatty acids of the (n-3) family and/or (n-6) family with 20 carbon atoms or less in the fatty acid chain (such as linoleic acid and alpha-linolenic acid).
  • a suitable assay such as one of the assays mentioned hereinabove
  • the amino acid sequence used in the invention is chosen from condensation enzymes involved in the First Step above that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for saturated fatty acids with 18 carbon atoms or less in the fatty acid chain, compared to both (1) saturated and unsaturated fatty acids with more than 18 carbon atoms in the fatty acid chain; as well as (2) unsaturated fatty acids of the (n-3) family and/or (n-6) family with 18 carbon atoms or less in the fatty acid chain.
  • the amino acid sequence used in the invention is chosen from condensation enzymes involved in the First Step above that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for palmitic acid and/or for stearic acid, compared to both (1) saturated and unsaturated fatty acids with more than 18 carbon atoms in the fatty acid chain; as well as (2) linoleic acid and/ox alpha-linolenic acid.
  • the amino acid sequence used in the invention is chosen from condensation enzymes involved in the First Step above that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for palmitic acid, compared to both (1) stearic acid; as well as (2) linoleic acid and/or alpha-linolenic acid.
  • a prefened, but non- limiting examples of such enzymes from mammals are LCE from mice (see Moon et al., supra) and its human equivalent (see again Moon et al., supra, as well as SEQ ID NOS: 1, 2 and 3), of which the latter is particularly prefened.
  • the amino acid sequence used in the invention is chosen from reductases involved in the reduction of the 3-ketoacyl-CoA using NADPH to form 3-hydroxyacyl-CoA (i.e. the Second Step above) and/or in the reduction of trans-2,3-enoyl-CoA to saturated acyl-CoA (i.e. the Fourth Step above).
  • reductases involved in the reduction of the 3-ketoacyl-CoA using NADPH to form 3-hydroxyacyl-CoA i.e. the Second Step above
  • trans-2,3-enoyl-CoA to saturated acyl-CoA
  • Some prefened, but non-limiting examples of such enzymes are KAR and TER, of which KAR is particularly prefened.
  • the amino acid sequence used in the invention may be chosen from the group consisting of ELOVL1, ELOVL2, ELOVL3, ELOVL4, ELOVL5, ELOVL6, KAR and TER, and in particular from ELOVL6, KAR and TER.
  • the invention relates to a method for identifying a compound that can be used in (the preparation of a pharmaceutical composition for) the prevention and/or treatment of metabolic diseases (e.g.
  • said method at least comprising the steps of: a) contacting an amino acid sequence that is involved in the elongation of fatty acids, and/or a host cell or host organism containing/expressing such an amino acid sequence, with a test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said amino acid sequence; and optionally b) detecting the signal that may thus be generated, said signal identifying a modulator of said amino acid sequence; in which the modulator thus identified can be used in (the preparation of a pharmaceutical composition for) the prevention and or treatment of metabolic diseases.
  • the modulators thus identified can be used in (the preparation of a pharmaceutical composition for) the prevention and/or treatment of metabolic diseases, and/or can be used to develop other compounds that can be used in (the preparation of a . pharmaceutical composition for) the prevention and/or treatment of metabolic diseases, as further described below.
  • the invention relates to a method for generating a signal that is representative for the interaction of a test chemical with an amino acid sequence involved in the elongation of fatty acids, said method at least comprising the steps of: a) contacting said amino acid sequence, or a host cell or host organism containing/expressing said amino acid sequence involved in the elongation of fatty acids, with said test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said amino acid sequence; and optionally b) detecting the signal that may thus be generated.
  • the invention relates to a method for identifying a modulator of an amino acid sequence that is involved in the elongation of fatty acids (e.g.
  • amino acid sequence involved in elongation of fatty acids may be any amino acid sequence that is involved in - e.g.
  • the amino acid sequence involved in elongation of fatty acids is preferably chosen from the group consisting of:
  • the amino acid sequence involved in elongation of fatty acids is chosen from the group consisting of: - condensation enzymes involved in the condensation between a fatty acyl-CoA and malonyl-CoA to form 3-ketoacyl-CoA that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for fatty acids with a length of the carbon chain of 24 carbon atoms or less; and
  • the amino acid sequence involved in elongation of fatty acids is chosen from the group consisting of:
  • the amino acid sequence involved in elongation of fatty acids is chosen from the group consisting of:
  • - condensation enzymes involved in the condensation between a fatty acyl-CoA and malonyl-CoA to form 3-ketoacyl-CoA that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for fatty acids with a length of the carbon chain of 18 carbon atoms or less; and - reductases involved in either the reduction of the 3-ketoacyl-CoA using NADPH to form 3-hydroxyacyl-CoA; and/or in the reduction of trans-2,3-enoyl-CoA to saturated acyl-CoA.
  • the amino acid sequence involved in elongation of fatty acids may be chosen from the group consisting of:
  • - condensation enzymes involved in the condensation between a fatty acyl-CoA and malonyl-CoA to form 3-ketoacyl-CoA that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for saturated fatty acids with 18 carbon atoms or less in the fatty acid chain, compared to both (1) saturated and unsaturated fatty acids with more than 18 carbon atoms in the fatty acid chain; as well as (2) unsaturated fatty acids of the (n-3) family and/or (n-6) family with 18 carbon atoms or less in the fatty acid chain; and
  • the amino acid sequence involved in elongation of fatty acids may be chosen from the group consisting of: condensation enzymes involved in the condensation between a fatty acyl-CoA and malonyl-CoA to form 3-ketoacyl-CoA that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for palmitic acid and/or for stearic acid, compared to both (1) saturated and unsaturated fatty acids with more than 18 carbon atoms in the fatty acid chain; as well as (2) linoleic acid and/or alpha-linolenic acid; and
  • the amino acid sequence involved in elongation of fatty acids may be chosen from the group consisting of: condensation enzymes involved in the condensation between a fatty acyl-CoA and malonyl-CoA to form 3-ketoacyl-CoA that have specificity (as determined by a suitable assay, such as one of the assays mentioned hereinabove) for palmitic acid, compared to both (1) stearic acid; as well as (2) linoleic acid and alpha-linolenic acid; and - reductases involved in either the reduction of the 3-ketoacyl-CoA using NADPH to form 3-hydroxyacyl-CoA; and/or in the reduction of trans-2,3-enoyl-
  • the amino acid sequence conesponding to a condensation enzyme contains at least a histidine-rich motif (H. ⁇ H), and preferably also contains an ELO-domain (as determined by SMARTTM analysis (see http://smart.embl-heidelberg.de/) and/or preferably by PFAM protein searchTM (see for example http://pfam.wustl.edu/).
  • the amino acid sequence conesponding to the reductase involved in the Second Step preferably contains an "adhjshort" domain (as determined by SMARTTM analysis (see http ://smart.embl- heidelberg.de/) and/or preferably by PFAM protein searchTM (see for example http://pfam.wustl.edu/).
  • the amino acid sequence conesponding to the reductase involved in the Fourth Step preferably contains an "ste ⁇ od_ short" domain (as determined by SMARTTM analysis (see http://smart.em.bl- heidelberg.de/) and/or preferably by PFAM protein searchTM (see for example http://pfam.wustl.edu/).
  • the amino acid involved in the elongation of fatty acids may be chosen from the group consisting of: ELOl, ELO2, ELO3, Cig30, Sscl, Ssc2, LCE, ELOVLl, ELOVL2, ELOVL3, ELOVL4, ELOVL5 (HELOl), ELOVL6, KAR and TER, and natural or synthetic analogs thereof, as further defined below.
  • the amino acid involved in the elongation of fatty acids may be chosen from the group consisting of: Cig30, Sscl, Ssc2, LCE, ELOVLl, ELOVL2, ELOVL3, ELOVL4, ELOVL5 (HELOl), ELOVL6, KAR and TER, and natural or synthetic analogs thereof (as further defined below). More in particular, the amino acid involved in the elongation of fatty acids may be chosen from the group consisting of: LCE, ELOVL6, KAR and TER, and natural or synthetic analogs thereof (as further defined below).
  • the amino acid involved in the elongation of fatty acids may be chosen from the group consisting of: ELOVL6, KAR and TER, and natural or synthetic analogs thereof (as further defined below).
  • the amino acid sequence involved in the elongation of fatty acids may be chosen from the group consisting of SEQ ID NOS: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33, and natural or synthetic analogs thereof (as further defined below).
  • the amino acid sequence involved in the elongation of fatty acids may be chosen from the group consisting of: SEQ ID NO: 3, 23 and/or 26, and natural or synthetic analogs thereof (as further defined below).
  • the invention also relates to the use of an amino acid sequence that is involved in the elongation of fatty acids (as defined above), and/or a host cell/host organism that contains and/or expresses such an amino acid sequence sequence, in one of the methods described above.
  • the term "host cell” also comprises cell fractions and/or preparations derived from such cells, such as cytosolic and in particular microsomal preparations (as mentioned below).
  • the invention also relates to compounds that can modulate (the biological activity of), and/or that can otherwise interact with, an amino acid that is involved in the elongation of fatty acids.
  • the invention also relates to compositions that contain such compounds, and in particular to pharmaceutical compositions that contain such compounds.
  • the invention further relates to the use of compounds that can modulate (the biological activity of), and/or that can otherwise interact with, an amino acid sequence that is involved in the elongation of fatty acids, in the preparation of pharmaceutical compositions, and in particular to the use of such compounds in the preparation of a pharmaceutical composition for the prevention and/or treatment of metabolic diseases.
  • the invention also relates to compounds that can be used in the prevention and/or treatment of metabolic diseases (as further defined below), which compounds have or can be identified and/or developed using an amino acid sequence involved in the elongation of fatty acids and/or a host cell or host organism that contains and/or expresses such an amino acid sequence.
  • the invention also relates to compositions that contain such compounds, and in particular to pharmaceutical compositions that contain said compounds, and to the use of such compounds in the preparation of a pharmaceutical composition, and in particular to the use of such compounds in the preparation of a pharmaceutical composition for the prevention or treatment of metabolic diseases.
  • all terms used in the present description have their usual meaning in the art, for which particular reference is made to the definitions given in WO98/06737 and EP 1 085 089.
  • the amino acid sequences of SEQ ID NOS: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33 were identified, and can be derived/isolated from/using human cells; in the manner as further described in the prior art refened to above, or in any other suitable manner known per se.
  • amino acid sequences of SEQ ID NOS: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33 may be isolated from the human cells and/or tissues using any technique(s) for protein isolation and/or purification known per se.
  • the amino acid sequences of SEQ ID NOS: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33 may be obtained by suitable expression of a suitable nucleotide sequence - such as one of the nucleotide sequences of SEQ ID NOS: 1, 2, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 22, 24 or 25, as applicable, or a suitable mutant thereof - in an appropriate host cell or host organism, as further described below.
  • Such natural analogs may again be obtained by isolating them from their natural source using any technique(s) for protein isolation and/or purification known per se, or alternatively by suitable expression of a suitable nucleotide sequence - such as a natural "mutant” as described herein - in an appropriate host cell or host organism, as further described below. It is also expected that - based upon the disclosure herein - the skilled person will be able to provide and/or derive synthetic "analogs" (as mentioned above) of one or more of the amino sequences of SEQ ID NOS: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33.
  • any analogs as described herein will have one or more, and preferably all, of the stmctural characteristics/conserved features refened to above for the sequences of SEQ ID NO: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33, such as - in the case of a condensation enzyme involved in the First Step above - the HXXHH motif and/or the ELO domain, and - in the case of a reductase involved in the Second Step above - an adh_short domain.
  • This may for instance be a N- and/or C- truncated amino acid sequence.
  • two or more parts or fragments of one or more amino acid sequences involved in the elongation of fatty acids may be suitably combined to provide a (further) amino acid sequence for use in the invention.
  • any such parts or fragments will be such that they comprise at least one continuous stretch of at least 5 amino acids, preferably at least 10 amino acids, more preferably at least 20 amino acids, even more preferably more than 30 amino acids, of one or more of the amino acid sequences of SEQ ID NO: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33.
  • any parts or fragments as described herein are such that they (at least) comprise the active/catalytic site of the conesponding amino acid sequence involved in the elongation of fatty acids and/or a binding domain of the conesponding amino acid sequence involved in the elongation of fatty acids, such as - in the case of a condensation enzyme involved in the First Step above - the HXXHH motif and/or (part of) the ELO domain, and - in the case of a reductase involved in the Second Step above - an adh_short domain.
  • such parts or fragments may find particular use in assay- and screening techniques (as generally described below) and/or (when said part or fragment is provided in crystalline form) in X-ray crystallography.
  • such parts or fragments of the amino acid sequences involved in the elongation of fatty acids may be obtained by suitable expression of a suitable nucleotide sequence used in the invention - such as a suitable part or fragment as described herein for the nucleotide sequences used in the invention - in an appropriate host cell or host organism, as further described below.
  • amino acid sequences used in the invention may also be provided by (chemically and/or enzymatically) modifying the side chain(s) of one or more amino acid residues of an amino acid sequence of SEQ ID NO: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33 or a part, fragment, (natural and/or synthetic) mutant, variant, allele, analogs, orthologs thereof, for example by one or more of the side chain modifications as described in WO 01/02560 and/or by incorporating (e.g. by insertion and/or substitution) one or more unnatural amino acid residues, again as described in WO 01/02560.
  • any analogs, parts and/or fragments as used herein will be such that they have a degree of "sequence identity", at the amino acid level, with one or more of the amino acid sequences of SEQ ID NOS 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33 of at least 50%, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, and in particular more than 90% and up to 95 % or more.
  • the percentage of "sequence identity" between a given amino acid sequence and one of the amino acid sequences of SEQ ID NOS: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33 maybe calculated by dividing [the number of amino acid residues in the given amino acid sequence that are identical to the amino acid residue at the corresponding position in the amino acid sequence of the relevant SEQ ID NO] by [the total number of amino acid residues in the given amino acid sequence] and multiplying by [100%], in which each deletion, insertion, substitution or addition of an amino acid residue - compared to the sequence of the relevant SEQ ID NO - is considered as a difference at a single amino acid (position).
  • the degree of sequence identity may be calculated using a known computer algorithm, such as those mentioned above.
  • sequence identity at the amino acid level may take into account so-called “conservative amino acid substitutions", which are well known in the art, for example from GB-A-2 357 768, WO 98/49185, WO 00/46383 and WO 01/09300; and (prefened) types and/or combinations of such substitutions maybe selected on the basis of the pertinent teachings from the references mentioned in WO 98/49185.
  • any analogs, parts and/or fragments as used herein will have a biological activity that is essentially similar to the biological activity described above for the sequences of SEQ ID NOS: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33, i.e.
  • an amino acid sequence used in the invention will (also) have a length (expressed as total number of amino acid residues), which is at least 50%, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, and in particular more than 90% and up to 95 % or more of the length of one or more of the amino acid sequence of SEQ ID NOS: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33.
  • a fusion of an amino acid sequence involved in the elongation of fatty acids (as described above) with one or more further amino acid sequences for example to provide a protein fusion.
  • fusions may be obtained by suitable expression of a suitable nucleotide sequence used in the invention - such as a suitable fusion of a nucleotide sequence used in the invention with one or more further coding sequences - in an appropriate host cell or host organism, as further described below.
  • fusions may comprise an amino acid sequence involved in the elongation of fatty acids fused with a reporter protein such as GFP, luciferase or another fluorescent protein moiety.
  • the fusion partner may be an amino acid sequence or residue that may be used in purification of the expressed amino acid sequence, for example using affinity techniques directed against said sequence or residue. Thereafter, said sequence or residue may be removed (e.g. by chemical or enzymatical cleavage) to provide the nucleotide sequence used in the invention (for this purpose, the sequence or residue may optionally be linked to the amino acid sequence involved in the elongation of fatty acids via a cleavable linker sequence).
  • any such fusion will have a biological activity that is essentially similar to the biological activity described above for the sequences of SEQ ID NOS: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33, i.e. to a degree of at least 10%, preferably at least 50 % more preferably at least 75%, and up to 90%, as measured by a suitable assay method, for example those mentioned in the prior art cited herein for each of these sequences.
  • amino acid sequences involved in the elongation of fatty acids may be obtained by suitable expression of a nucleotide sequence encoding such an amino acid sequence in a suitable host organism, as further described below.
  • said nucleotide sequence may be in the form of a genetic construct, also as further described below.
  • nucleotide sequences of SEQ ID NOS: 1, 2, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 22, 24 or 25 were identified, and can be derived/isolated from/using human cells and/or tissues; in any suitable manner known per se, including but not limited to PCR starting from human genomic DNA or a library of human cDNA, using primers designed on the basis of the relevant sequence. Also, it is expected that - based upon the disclosure herein - the skilled person will be able to identify, derive and/or isolate natural "mutants" (as mentioned above) of the above nucleotide sequences. For example, such mutants could be derived from other species (in which case these mutants will also be refened to herein as "orthologs").
  • species from which such orthologs could be derived include, but are not limited to species of unicellular and/or micro-organisms such as bacteria, and yeast, invertebrate multicellular organisms as such as insects and nematodes (for example, agronomically harmful insect or nematode species); - vertebrate multicellular organisms as such as fish, birds, reptiles, amphibians and mammals;
  • a natural ortholog is derived from a mammal such as a mouse, rat, rabbit or dog and the further species mentioned above.
  • Such natural mutants may be obtained in a manner essentially analogous to the methods described in the prior art refened to above, or alternatively by: construction of a DNA library from the species of interest in an appropriate expression vector system, followed by direct expression of the mutant sequence; construction of a DNA library from the species of interest in an appropriate expression vector system, followed by screening of said library with a probe used in the invention (as described below) and/or with a(nother) nucleotide sequence used in the invention; isolation of mRNA that encodes the mutant sequence from the species of interest, followed by cDNA synthesis using reverse transcriptase; and/or by any other suitable method(s) or technique(s) known per se, for which reference is for instance made to the standard handbooks, such as Sambrook et al, "Molecular Cloning: A Laboratory Manual” ( 2nd.ed.), Vols.
  • Techniques for generating such synthetic sequences will be clear to the skilled person and may for instance include, but are not limited to, automated DNA synthesis; site-directed mutagenesis; combining two or more parts of one or more naturally occuning sequences, introduction of mutations that lead to the expression of a truncated expression product; introduction of one or more restriction sites (e.g. to create casettes and/or regions that may easily be digested and or ligated using suitable restriction enzymes), and/or the introduction of mutations by means of a PCR reaction using one or more "mismatched" primers, using for example a sequence of a naturally occuning GPCR as a template.
  • any mutants used will encode amino acid sequences having one or more, and preferably all, of the structural characteristics/conserved features refened to for the elongation enzymes above (such as - in the case of a condensation enzyme involved in the First Step above - an HXXHH motif and/or an ELO domain in the case of an enzyme involved in the condensation reaction of the First Step above, and - in the case of a reductase involved in the Second Step above - an adh_short domain) and in particular the active site(s) and/or catalytic domain(s).
  • the "mutants" used are (also) such that they are capable of hybridizing with one or more of the nucleotide sequences of SEQ ID NO's 1 , 2, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 22, 24 or 25, i.e. under conditions of "moderate stringency", and preferably under conditions of "high stringency".
  • conditions of “moderate stringency” and preferably under conditions of "high stringency”.
  • any “mutants” used will preferably have a degree of "sequence identity", at the nucleotide level, with one or more of the nucleotide sequences of SEQ ID NOS: 1, 2, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 22, 24 or 25 of at least 50%, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, and in particular more than 90% ⁇ , and up to 95% or more.
  • the percentage of "sequence identity" between a given nucleotide sequence and one of the nucleotide sequences used in the invention may be calculated by dividing [the number ofnucleotides in the given nucleotide sequence that are identical to the nucleotide at the corresponding position in the nucleotide sequence of the relevant SEQ ID NO] by [the total number ofnucleotides in the given nucleotide sequence] and multiplying by [100%], in which each deletion, insertion, substitution or addition of a nucleotide - compared to the sequence of the relevant SEQ ID NO - is considered as a difference at a single nucleotide (position).
  • the degree of sequence identity may be calculated using a known computer algorithm for sequence alignment such as NCBI Blast v2.0, using standard settings. Some other techniques, computer algorithms and settings for determining the degree of sequence identity are for example described in EP 0 967 284, EP 1 085 089, WO 00/55318, WO 00/78972, WO 98/49185 and GB 2 357 768-A.
  • the nucleotide sequences used in the invention when in the form of a nucleic acid, may be DNA or RNA, and may be single stranded or double stranded.
  • the nucleotide sequences used in the invention may be genomic DNA, cDNA or synthetic DNA (such as DNA with a codon usage that has been specifically adapted for expression in the intended host cell or host organism).
  • the nucleotide sequences used in the invention may contain intron sequences, and also generally comprises different splice variants. It is also within the scope used in the invention to use a fusion of a nucleotide sequence used in the invention (as described above) with one or more further nucleotide sequence(s), including but not limited to one or more coding sequences, non-coding sequences and/or regulatory sequences.
  • the one or more further nucleotide sequences are operably connected (as described below) to the nucleotide sequence used in the invention (for example so that, when the further nucleotide sequence is a coding sequence, the nucleotide fusion encodes a protein fusion as described below).
  • Another embodiment used in the invention relates to a nucleic acid probe that is capable of hybridizing with a nucleotide sequence of SED ID NO: 1, 2, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 22, 24 or 25 under conditions of moderate stringency, preferably under conditions of high stringency, and in particular under stringent conditions (all as described above).
  • nucleotide probes may for instance be used for detecting and/or isolating a(nother) nucleotide sequence used in the invention and/or as a primer for amplifying a nucleotide sequence used in the invention; all using techniques known per se, for which reference is again made to the general handbooks such as Sambrook et al. and Ausubel et al. mentioned above.
  • probes can be designed by the skilled person starting from a nucleotide sequence and/or amino acid sequence used in the invention - and in particular one or more of the sequences of SEQ ID NOS 1, 2, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 22, 24 or 25.
  • the nucleic acids used in the invention may also be in the form of a genetic construct, which may for example comprise: a) the nucleotide sequence as described above; operably connected to: b) one or more regulatory elements, such as a promoter and optionally a suitable terminator; and optionally also: c) one or more further elements of genetic constructs known per se; in which the terms "regulatory element”, “promoter”, “terminator”, “further elements” and “operably connected” have the meanings indicated hereinbelow.
  • Such genetic constructs may be DNA or RNA, and are preferably double-stranded DNA.
  • the constructs may also be in a form suitable for transformation of the intended host cell or host organism, in a form suitable for integration into the genomic DNA of the intended host cell or in a form suitable independent replication, maintenance and/or inheritance in the intended host organism.
  • the genetic construct may be in the form of a vector, such as for example a plasmid, cosmid, YAC, a viral vector or transposon.
  • the vector may be an expression vector, i.e. a vector that can provide for expression in vitro and/or in vivo (e.g. in a suitable host cell and/or host organism as described below).
  • the genetic construct(s) used in the invention may generally contain one or more suitable regulatory elements (such as a suitable promoter(s), enhancer(s), terminator(s), etc.), 3'- or 5'-UTR sequences, leader sequences, selection markers, expression markers/reporter genes, and/or elements that may facilitate or increase (the efficiency of) transformation or integration.
  • suitable regulatory elements such as a suitable promoter(s), enhancer(s), terminator(s), etc.
  • 3'- or 5'-UTR sequences such as a suitable promoter(s), enhancer(s), terminator(s), etc.
  • 3'- or 5'-UTR sequences such as a suitable promoter(s), enhancer(s), terminator(s), etc.
  • 3'- or 5'-UTR sequences such as a suitable promoter(s), enhancer(s), terminator(s), etc.
  • 3'- or 5'-UTR sequences such as a suitable promoter(s), enhancer(s), terminator(s), etc
  • the one or more further elements are "operably linked" to the nucleotide sequence(s) used in the invention and/or to each other, by which is generally meant that they are in a functional relationship with each other.
  • a promoter is considered “operably linked” to a coding sequence if said promoter is able to initiate or otherwise control/regulate the transcription and/or the expression of a coding sequence (in which said coding sequence should be understood as being “under the control of' said promotor)
  • two nucleotide sequences when operably linked, they will be in the same orientation and usually also in the same reading frame. They will usually also be essentially contiguous, although this may also not be required.
  • the optional further elements of the genetic construct(s) used in the invention are such that they are capable of providing their intended biological function in the intended host cell or host organism.
  • a promoter, enhancer or terminator should be "operable" in the intended host cell or host organism, by which is meant that (for example) said promoter should be capable of initiating or otherwise controlling/regulating the transcription and/or the expression of a nucleotide sequence - e.g. a coding sequence - to which it is operably linked (as defined above).
  • Such a promoter may be a constitutive promoter or an inducible promoter, and may also be such that it (only) provides for expression in a specific stage of development of the host cell or host organism, and/or such that it (only) provides for expression in a specific cell, tissue, organ or part of a multicellular host organism.
  • Some particularly prefened promoters include, but are not limited to those present in the expression vectors refened to below.
  • a selection marker should be such that it allows - i.e. under appropriate selection conditions - host cells and/or host organisms that have been (successfully) transformed with the nucleotide sequence used in the invention to be distinguished from host cells/organisms that have not been (successfully) transformed.
  • markers are genes that provide resistance against antibiotics (such as kanamycine or ampicillme), genes that provide for temperature resistance, or genes that allow the host cell or host organism to be maintained in the absence of certain factors, compounds and/or (food) components in the medium that are essential for survival of the non-transformed cells or organisms.
  • a leader sequence should be such that - in the intended host cell or host organism - it allows for the desired post-translational modifications and/or such that it directs the transcribed mRNA to a desired part or organelle of a cell.
  • a leader sequence may also allow for secretion of the expression product from said cell.
  • the leader sequence may be any pro-, pre-, or prepro-sequence operable in the host cell or host organism.
  • An expression marker or reporter gene should be such that - in the host cell or host organism - it allows for detection of the expression of (a gene or nucleotide sequence present on) the genetic construct.
  • An expression marker may optionally also allow for the localisation of the expressed product, e.g. in a specific part or organelle of a cell and/or in (a) specific cell(s), tissue(s), organ(s) or part(s) of a multicellular organism.
  • Such reporter genes may also be expressed as a protein fusion with the amino acid sequence involved in the elongation of fatty acids.
  • Some prefened, but non-limiting examples include fluorescent proteins such as GFP.
  • fluorescent proteins such as GFP.
  • the promoters, selection markers, leader sequences, expression markers and further elements that may be present/used in the genetic constructs used in the invention - such as terminators, transcriptional and/or translational enhancers and/or integration factors - reference is made to the general handbooks such as Sambrook et al. and Ausubel et al. mentioned above, to W.B. Wood et al., "77ze nematode Caenorhabditis elegans", Cold Spring Harbor Laboratory Press (1988) and D.L. Riddle et al., "C.
  • suitable expression vectors include: vectors for expression in mammalian cells: pMAMneo (Clontech), pcDNA3 (Invitrogen), pMC 1 neo (Stratagene), pSG5 (Stratagene), EBO-pS V2-neo (ATCC 37593), pBPV-1 (8-2) (ATCC 37110), pdBPV-MMTneo (342-12) (ATCC 37224), pRSVgpt (ATCC37199), pRSVneo (ATCC37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460) and 1ZD35 (ATCC 37565); vectors for expression in bacterials cells:
  • the nucleotide sequences and/or genetic constructs used in the invention may be used to transform a host cell or host organism.
  • the host cell may be any suitable (fungal, prokaryotic or eukaryotic) cell or cell line, for example: a bacterial strain, including but not limited to strains of E.coli, Bacillus. Streptomyces and Pseudomonas; - a fungal cell, including but not limited to cells from species of Aspergillus and Trichoderma; a yeast cell, including but not limited to cells from species of Kluyveromyces or Saccharomyces; an amphibian cell or cell line, such as Xenopus oocytes.
  • the host cell may be an insect-derived cell or cell line, such as: cells/cell lines derived from lepidoptera, including but not limited to Spodoptera SF9 and Sf21 cells, cells/cell lines derived from Drosophila, such as Schneider and Kc cells; and/or - cells/cell lines derived from a pest species of interest (as mentioned below), such as from Heliothis virescens.
  • the host cell is a mammalian cell or cell line, for example derived from the mammals refened to above.
  • the host cell is a cell or cell line derived from a human, from the mammals including but not limited to CHO- and BHK-cells and human cells or cell lines such as HeLa and COS.
  • the cell or cell line may be human cell or cell line which is related to metabolic processes or metabolic disease and/or used as a cellular model for metabolic disease, including but not limited to liver cells or cell lines, adipocytes or muscle cells or cell lines such as HEPG2 cells, 3T3L1 adipocytes, CTC12 cells and L6 myotubes.
  • the host organism may be any suitable multicellular (vertebrate or invertebrate) organism, including but not limited to: a nematode, including but not limited to nematodes from the genus Caenorhabditis, such as C.elegans, an insect, including but not limited to species of Drosophila and/or a specific pest species of interest (such as those mentioned above); other well known model organisms, such as zebrafish; a mammal such as a rat or mouse; Other suitable host cells or host organisms will be clear to the skilled person, for example from the handbooks and patent applications mentioned above.
  • a nematode including but not limited to nematodes from the genus Caenorhabditis, such as C.elegans
  • an insect including but not limited to species of Drosophila and/or a specific pest species of interest (such as those mentioned above)
  • other well known model organisms such as zebrafish
  • a mammal such as a rat or
  • nucleotide sequence used in the invention when expressed in a multicellular organism, it may be expressed throughout the entire organism, or only in one or more specific cells, tissues, organs and/or parts thereof, for example by expression under the control of a promoter that is specific for said cell(s), tissue(s), organ(s) or part(s).
  • the nucleotide sequence may also be expressed during only a specific stage of development or life cycle of the host cell or host organism, again for example by expression under the control of a promoter that is specific for said stage of development or life cycle.
  • said expression may be constitutive, transient and/or inducible.
  • the expression of a nucleotide sequence used in the invention in a host cell or host organism may be party or totally reduced (i.e. knocked out), compared to the original (e.g. native) host cell or host organism.
  • This may for instance be achieved in a transient manner using antisense and/or RNA-interference techniques well known in the art, or in a constitutive manner using random, site specific and/or chemical mutagenesis of the nucleotide sequence used in the invention, or any other suitable techniques for generating "knock-down" or "knock-out” animals.
  • Suitable transformation techniques will be clear to the skilled person and may depend on the intended host cell/host organism and the genetic construct to be used.
  • Suitable techniques include ballistic transformation, (micro-)injection, transfection (e.g. using suitable transposons), electroporation and lipofection.
  • a step for detecting and selecting those host cells or host organisms that have been successivefully transformed with the nucleotide sequence/genetic construct used in the invention may be performed. This may for instance be a selection step based on a selectable marker present in the genetic construct used in the invention or a step involving the detection of the amino acid sequence involved in the elongation of fatty acids, e.g. using specific antibodies.
  • the transformed host cell (which may be in the form or a stable cell line) or host organisms (which may be in the form of a stable mutant line or strain) form further aspects of the present invention.
  • these host cells or host organisms are such that they express, or are (at least) capable of expressing (e.g. under suitable conditions), an amino acid sequence involved in the elongation of fatty acids (and in case of a host organism: in at least one cell, part, tissue or organ thereof).
  • the invention also includes further generations, progeny and/or offspring of the host cell or host organism used in the invention, that may for instance be obtained by cell division or by sexual or asexual reproduction.
  • the transformed host cell or transformed host organism may generally be kept, maintained and/or cultured under conditions such that the (desired) amino acid sequence involved in the elongation of fatty acids is expressed/produced. Suitable conditions will be clear to the skilled person and will usually depend upon the host cell/host organism used, as well as on the regulatory elements that control the expression of the (relevant) nucleotide sequence used in the invention. Again, reference is made to the handbooks and patent applications mentioned above in the paragraphs on the genetic constructs used in the invention.
  • suitable conditions may include the use of a suitable medium, the presence of a suitable source of food and/or suitable nutrients, the use of a suitable temperature, and optionally the presence of a suitable inducing factor or compound (e.g. when the nucleotide sequences used in the invention are under the control of an inducible promoter); all of which maybe selected by the skilled person.
  • a suitable inducing factor or compound e.g. when the nucleotide sequences used in the invention are under the control of an inducible promoter
  • the amino acid sequences involved in the elongation of fatty acids may be expressed in a constitutive manner, in a transient manner, or only when suitably induced.
  • amino acid sequence involved in the elongation of fatty acids may (first) be generated in an immature form (as mentioned above), which may then be subjected to post-translational modification, depending on the host cell/host organism used. Also, the amino acid sequence involved in the elongation of fatty acids may be glycosylated, again depending on the host cell/host organism used.
  • the amino acid sequence involved in the elongation of fatty acids may then be isolated from the host cell/host organism and/or from the medium in which said host cell or host organism was cultivated, using protein isolation and/or purification techniques known per se, such as (preparative) chromatography and/or electrophoresis techniques, differential precipitation techniques, affinity techniques (e.g. using a specific, cleavable amino acid sequence fused with the amino acid sequence involved in the elongation of fatty acids) and/or preparative immunological techniques (i.e. using antibodies against the amino acid sequence to be isolated).
  • the amino acid sequence thus obtained may also be used to generate antibodies specifically against said sequence or an antigenic part or epitope thereof.
  • Such antibodies which form a further aspect of the invention, may be generated in a manner known per se, for example as described in GB-A-2 357 768, US-A- 5,693,492, WO 95/32734, WO 96/23882, WO 98/02456, WO 98/41633 and or WO 98/49306, and/or as described in the prior art refened to above.
  • such methods will involve immunizing a immunocompetent host with the pertinent amino acid sequence involved in the elongation of fatty acids or an immatoriumic part thereof (such as a specific epitope), in amount(s) and according to a regimen such that antibodies against said amino acid sequence are raised, and than harvesting the antibodies thus generated, e.g. from blood or serum derived from said host.
  • polyclonal antibodies can be obtained by immunizing a suitable host such as a goat, rabbit, sheep, rat, pig or mouse with (an epitope of) an amino acid sequence involved in the elongation of fatty acids, optionally with the use of an immunogenic carrier (such as bovine serum albumin or keyhole limpet hemocyanin) and/or an adjuvant such as Freund's, saponin, ISCOM's, aluminium hydroxide or a similar mineral gel, or keyhole limpet hemocyanin or a similar surface active substance.
  • an immunogenic carrier such as bovine serum albumin or keyhole limpet hemocyanin
  • an adjuvant such as Freund's, saponin, ISCOM's, aluminium hydroxide or a similar mineral gel, or keyhole limpet hemocyanin or a similar surface active substance.
  • the antibodies can be isolated from blood or serum taken from the immunized animal in a manner known per se, which optionally may involve a step of screening for an antibody with desired properties (i.e. specificity) using known immunoassay techniques, for which reference is again made to for instance WO 96/23882.
  • Monoclonal antibodies may for example be produced using continuous cell lines in culture, including hybridoma-based and similar techniques, again essentially as described in the above cited references.
  • cells and cell lines that produce monoclonal antibodies against an amino acid sequence involved in the elongation of fatty acids form a further aspect of the invention, as do methods for producing antibodies against amino acid sequences involved in the elongation of fatty acids, which methods may generally involve cultivating such a cell and isolating the antibodies from the culture (medium), again using techniques known per se.
  • Fab-fragments against the amino acid sequences involved in the elongation of fatty acids may be obtained by digestion of an antibody with pepsin or another protease, reducing disulfide-linkages and treatment with papain and a reducing agent, respectively.
  • Fab-expression libraries may for instance be obtained by the method of Huse et al., 1989, Science 245:1275-1281.
  • the nucleotide sequences used in the invention, the amino acid sequences used in the invention, and/or a host cell or host organism that expresses such an amino acid sequence may also be used in an assay or assay method generally (including but not limited to diagnostic assays and/or assays to determing the presense and/or absence of specific mutations and/or genetic markers, for example to determine susceptibility for a condition or disease associated with such a mutation or marker), and in particular in an assay to identify and/or (further) develop compounds and/or other factors that can modulate the (biological) activity of, and/or that can otherwise interact with, the amino acid sequences involved in the elongation of fatty acids, and such uses form further aspects of the invention.
  • a modulator is a compound or factor that can enhance, inhibit/reduce or otherwise alter, influence or affect (collectively refened to as "modulation") a functional property of a biological activity or process (for example, the biological activity of an amino acid sequence involved in the elongation of fatty acids).
  • the amino acid sequence involved in the elongation of fatty acids may serve as a target for modulation in vitro (e.g. as part of an assay or screen) and/or for modulation in vivo (e.g. for modulation by a compound or factor that is known to modulate the target, which compound or factor may for example be used as an active compound for agrochemical, veterinary and/or pharmaceutical use).
  • the amino acid sequences, host cells and/or host organisms used in the invention may be used as part of an assay or screen that may be used to identify and/or develop modulators of the amino acid sequence involved in the elongation of fatty acids, such as a primary screen (e.g.
  • a screen used to identify modulators of the target from a set or library of test chemicals with unknown activity with respect to the target) and/or a secondary assay e.g. an assay used for validating hits from a primary screen and/or used in optimizing hit molecules, e.g. as part of hits-to-leads chemistry.
  • a secondary assay e.g. an assay used for validating hits from a primary screen and/or used in optimizing hit molecules, e.g. as part of hits-to-leads chemistry.
  • such an assay or screen may be configured as an in vitro assay or screen, which will generally involve binding of the compound or factor to be tested as a potential modulator for the target (hereinbelow also refened to as "test chemical") to the target, upon which a signal generated by said binding is measured.
  • an assay or screen may be configured as a binding assay or screen, in which the test chemical is used to displace a detectable ligand from the target (e.g. a radioactive or fluorescent ligand), upon which the amount of ligand displaced from the target by the modulator is determined.
  • a detectable ligand from the target e.g. a radioactive or fluorescent ligand
  • reductases involved the elongation of fatty acids such as KAR and TER may be screened for modulators (such as inhibitors) using one of the following techniques: 1) Radioactive detection method based on the use of a radioactive labeled substrate, for example 1 C labeled Malonyl-CoA (see also Moon and Horton, supra).
  • the fatty acid chain e.g. palmitoyl-CoA
  • streptavidin directly or via biotin
  • BSA as used by Moon and Horton
  • an SPATM assay can be envisaged in which the palmitoyl-CoA is attached to an SPA bead.
  • the 14 C would be incorporated to the fatty acid chain fixed to the SPA bead, generating scintillation from the bead due to the proximity of the radioactive label. (Amersham patented technology).
  • the advantage of this assay configuration would be that no washing is required.
  • Luminescent assay based on the detection of FMN cofactor (see for example Warne, et al, 2002, Poster #2448, 8th Annual Conference and Exhibition of the Society for Biomolecular Screening, September 22-26th 2002, The Hague, the Netherlands), which is suitable for the detection of the activity of all the three enzymes involved in the fatty acid elongation. This may be performed either by using the isolated enzyme, or a suitable microsomal preparation containing tow or more, or essentially all, enzymes of the elongation pathway. 3) Colorimetric detection of NADH consumption. In the assay described by Moon and Horton, supra, NADH is used as a source of hydrogen in the reduction of the 3- ketoacyl-CoA.
  • a colorimetric method has been described recently to detect directly the consumption of NADH and formation of NAD (See Mayer and Arnold, 2002, J. Biomol. Screening, Vol.7 (2), ppl35). In this way, the reduction reaction catalyzed by KAR can be monitored by measuring the consumption of NADH. 4) Fluorescence Resonance Electron Transfer (FRET) can be detected when two suitable fluorescent molecules are brought in proximity of each other.
  • FRET Fluorescence Resonance Electron Transfer
  • the enzymatic reaction performed by KAR is a reduction, it should be in principle possible to detect product formation by FRET between the individually labeled reactants, provided the fluorophore are chosen such (especially respective to the size of malonyl-CoA) that steric hindrances can avoided; and/or by one of the assays described in the prior art for KAR and TER, such as the prior art mentioned herein, which assay may optionally be adapted and/or configured for automation and/or medium to high through-put
  • the condensation enzymes involved in the First Step above could also be screened using a luminescent assay based on the detection of FMN cofactor, as described under 2) above; and/or by one of the assays described in the prior art for said condensation enzymes, such as the prior art mentioned herein, which assay may optionally be adapted and/or configured for automation and/or medium to high through- put Assays or screens for identifying compounds that can interact with the amino acid sequences involved in the elongation of fatty acids
  • the influence of the compound on the elongase(s) may then be determined by exposing the cells to a suitable substrate and the compound(s) to be tested, analogous to the methods described in the references just cited.
  • Such cell-based methods may also allow, with advantage, to screen the influence of the compound(s) to be tested not only on the elongase(s) to be screened, but also on the whole elongation pathway or cell, and may as such form a suitable secondary assay for confirmation of hits generated using an in vitro HTS screen as described above.
  • the luminescent assay based on the detection of FMN cofactor described under 2) above could be used, using a suitable microsomal preparation containing all enzymes from the elongation pathway.
  • Suitable cells or cell lines for such cell based assays include those mentioned above.
  • the cell or cell line may be a mammalian, and in particular human, cell or cell line which is related to metabolic processes or metabolic disease and/or used as a cellular model for metabolic disease, including but not limited to liver cells or cell lines, adipocytes or muscle cells or cell lines such as HEPG2 cells, 3T3L1 adipocytes, CTC12 cells and L6 myotubes.
  • adipocytes or muscle cells or cell lines such as HEPG2 cells, 3T3L1 adipocytes, CTC12 cells and L6 myotubes.
  • an assay or screen may also be configured as an whole animal screen, in which a host organism used in the invention is contacted with/exposed to a test chemical, upon which at least one biological response (such as a phenotypical, behavioural and/or fysiological change, including but not limited to paralysis or death) by the host organism is measured.
  • a biological response such as a phenotypical, behavioural and/or fysiological change, including but not limited to paralysis or death
  • Such screens may be carried out in any model organism known per se, including but not limited to yeast, Drosophila, zebrafish or C. elegans.
  • the assays and screens described above will comprise at least one step in which the test chemical is contacted with the target (and/or with a host cell or host organism that expresses the target), and in particular in such a way that a signal is generated that is representative for the modulation of the target by the test chemical. In a further step, said signal may then be detected.
  • the compounds that may be tested using the methods of the invention are generally described below.
  • the assays and screens used in the invention may be canied out at medium throughput to high throughput, for example in an automated fashion using suitable robotics.
  • the method used in the invention may be canied out by contacting the target with the test compound in a well of a multi- well plate, such as a standard 24, 96, 384, 1536 or 3456 well plate.
  • a multi- well plate such as a standard 24, 96, 384, 1536 or 3456 well plate.
  • the target or host cell/host organism will be contacted with only a single test compound.
  • the compound used when the compound is intended to interact with a condensation enzyme involved in the First Step above, is also preferably such that it is selective for one condensation enzyme (i.e. with a specific substrate specificity, as described above) compared to another condensation enzyme (i.e. with a different substrate specificity).
  • the compound used is preferably such that it is selective for the condensation enzymes which are indicated hereinabove as prefened, compared to condensation enzymes that indicated hereinabove as being less prefened.
  • the compound used is preferably selective for a condensation enzyme that has specificity (as defined above) for fatty acids with a length of the carbon chain of 20 carbon atoms or less, compared to a condensation enzyme that has specificity for fatty acids with a length of the carbon chain of more than 20 carbon atoms.
  • the compound used is preferably such that is has specificity for LCE and/or ELOVL6, compared to other condensation enzymes.
  • the selectivity of a compound for one enzyme/isoform compared to another may be determined in a manner known per se, which generally involves comparing the influence the compound has on the activity of one enzyme/isoform compared to another, using a suitable assay (usually at the same concentration(s) of compound, enzyme and substrate).
  • the selectivity may be established by comparing the IC50 or ED50 values of the compound with respect of each enzyme, as is well known in the art, with a lower ED50 or IC50 value with respect to a first enzyme compared to a second enzyme being an indication that the compound is more selective for the first enzyme compared to the second.
  • a compound is considered selective for a first enzyme compared to a second when the ED50 or IC50 value of the compound with respect to the first enzyme is less than 90%, preferably less than 50%, more preferably less than 25%, even more preferably less than 10%, an in particular less than 5%, such as less than 1% or even less than 0.1%, of the ED50 or IC50 value for the second enzyme.
  • a test chemical may be used per se as a modulator of the amino relevant amino acid sequence involved in the elongation of fatty acids (e.g.
  • nucleotide sequences, amino acid sequences, host cells/host organisms and/or methods used in the invention may find further use in such optimization methodology, for example as (part of) secondary assays.
  • the invention is not particularly limited to any specific manner or mechanism in/via which the modulator (e.g. the test chemical, compound and/or factor) modulates, or interacts with, the target (in vivo and/or in vitro).
  • the modulator may an agonist, an antagonist, an inverse agonist, a partial agonist, a competitive inhibitor, a non- competitive inhibitor, a cofactor, an allosteric inhibitor or other allosteric factor for the target, and/or may be a compound or factor that enhances or reduces binding of target to another biological component associated with its (biological) activity, such as another protein or polypeptide, a receptor, or a part of organelle of a cell.
  • the modulator may bind with the target (at the active site, at an allosteric site, at a binding domain and/or at another site on the target, e.g.
  • the test chemical/modulator may for instance be: an analog of a known substrate of the target; - an oligopeptide, e.g. comprising between 2 and 20, preferably between 3 and 15 amino acid residues; an antisense or double stranded RNA molecule; a protein, polypeptide; a cofactor or an analog of a cofactor.
  • the compound is an inhibitor of the target, although the invention in its broadest sense is not limited thereto.
  • the test chemical/modulator may also be a reference compound or factor, which may be a compound that is known to modulate or otherwise interact with the target (e.g. a known substrate or inhibitor for the target) or a compound or factor that is generally known compound that is known to modulate or otherwise interact with other members from the general class to which the target belongs (e.g. a known substrate or inhibitor of said class).
  • the compound(s) will be "small molecules", by which is generally meant herein a molecular entity with a molecular weight of less than 1500, preferably less than 1000.
  • This may for example be an organic, inorganic or organometallic molecule, which may also be in the form or a suitable salt, such as a water-soluble salt; and may also be a complex, chelate and/or a similar molecular entities, as long as its (overall) molecular weight is within the range indicated above.
  • a "small molecule" has been designed according, and/or meets the criteria of, at least one, preferably at least any two, more preferably at least any three, and up to all of the so-called Lipinski rules for drug likeness prediction (vide Lipinksi et al., Advanced Drug Delivery Reviews 23 (1997), pages 3-25).
  • small molecules which meet these criteria are particularly suited (as starting points) for the design and/or development of pharmaceuticals for human use, and may for instance be used as starting points for hits-to-leads chemistry, and/or as starting points for lead development (in which the methods used in the invention may also be applied).
  • the design of such small molecules (as well as the design of libraries consisting of such small molecules) will preferably also take into account the presence of pharmacophore points, for example according to the methods described by I. Muegge et al., J. Med. Chem. 44, 12 (2001), pages 1-6 and the documents cited herein.
  • small peptide generally covers (oligo)peptides that contain a total of between 2 and 35, such as for example between 3 and 25, amino acids (e.g. in one or more connected chains, and preferably a single chain). It will be clear that some of these small peptides will also be included in the term small molecule as used herein, depending on their molecular weight.
  • the invention is used to screen a set or library of (related or otherwise unrelated) small molecules, for example a standard "robustness set", a primary screening library (e.g. of otherwise unrelated compounds), a combinatorial library, a series of closely related chemical analogos.
  • Such sets or libraries will be clear to the skilled person, and may for instance include, but are not limited to, such commercially available chemical libraries such as the various libraries available from Tocris Cookson, Bristol, UK.
  • the modulators thus identified by the methods used in the invention can be used in (the preparation of a pharmaceutical composition for) the prevention and/or treatment of metabolic diseases, and/or can be used to develop other compounds that can be used in (the preparation of a pharmaceutical composition for) the prevention and/or treatment of metabolic diseases, i.e. as already outlined above.
  • the use of the human amino acid sequences of SEQ ID NOS: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33, and/or of sequences derived therefrom (such as analogs, parts, fragments, and/or fusions thereof as described hereinabove), and of host cells/host organisms containing/expressing these, are usually prefened, in particular when the invention is used to develop compounds for pharmaceutical use.
  • the compounds and/or factors that have been identified and/or developed as modulators of the amino acid sequences involved in the elongation of fatty acids may be useful as active substances in the pharmaceutical field, for example in the preparation of pharmaceutical compositions, and both such modulators as well as (pharmaceutical) compositions containing them further aspects of the invention.
  • the compounds and composition of the invention may be used in
  • the preparation of pharmaceutical compositions for the prevention (e.g. prophylaxis) and/or treatment of metabolic diseases (which for the purposes herein in its broadest sense also includes preventing, treating and or alleviating the symptoms and/or complications of such metabolic diseases).
  • such compounds and composition may be used in (the preparation of pharmaceutical compositions for) the prevention (e.g. prophylaxis) and/or treatment of metabolic diseases (which for the purposes herein in its broadest sense also includes preventing, treating and/or alleviating the symptoms and/or complications of such metabolic diseases).
  • the compounds and compositions of the invention may be used for preventing and/or treating: hyperglycemic conditions and/or other conditions and/or diseases that are (primarily) associated with (the response or sensitivity to) insulin, including but not limited to all forms of diabetes and disorders resulting from insulin resistance, such as Type I and Type II diabetes, as well as severe insulin resistance, hyperinsulinemia, and hyperlipidemia, e.g., obese subjects, and insulin-resistant diabetes, such as Mendenhall's Syndrome, Werner Syndrome, leprechaunism, lipoatrophic diabetes, and other lipoatrophies; conditions caused or usually associated with hyperglycemic conditions and/or obesity, such as hypertension, osteoporosis and/or lipodystrophy.
  • hyperglycemic conditions and/or other conditions and/or diseases that are (primarily) associated with (the response or sensitivity to) insulin including but not limited to all forms of diabetes and disorders resulting from insulin resistance, such as Type I and Type II diabetes, as well as severe insulin resistance, hyperinsulinemia, and hyperlipidemia
  • diabetes - so-called “metabolic syndrome” (also known as “Syndrome X”) which is a condition where several of the following conditions coexist: hypertension; insulin resistance; diabetes; dyslipidemia; and/or obesity.
  • the compounds and compositions of the invention may be used for preventing and/or treating diabetes, especially Type I and Type II diabetes.
  • Diabetes itself refers to a progressive disease of carbohydrate metabolism involving inadequate production or utilization of insulin and is characterized by hyperglycemia and glycosuria.
  • the amino acid sequences involved in the elongation of fatty acids and in particular the nucleotide sequences used in the invention, and more in particular the human amino acid sequences and nucleotide sequences used in the invention may be used for diagnostic purposes, for example as part of diagnostic assays and/or as part of kits for performing such assays (in which such a kit will comprise at least a nucleotide sequence used in the invention, may be suitably packaged (e.g. in a suitbale container) and may optionally further comprise one or more elements for such kits known per se, such as suitable reagents, buffers or other solvents, and instructions for use).
  • amino acid sequences and nucleotide sequences used in the invention may be used for diagnostic purposes relating to one or more of the metabolic diseases indicated above, for example as assays to determine the presense and/or absence in an individual of specific mutations and/or genetic markers that relate to one or more of the metabolic diseases refened to above, to determine the susceptibility and/or any predisposition for any of the metabolic diseases refened to above in an individual, to determine if any genetically determined factors contribute or even cause (in full or in part) a metabolic disease in an individual, determine and/or to confirm the kind of metabolic disease from which an individual suffers, and/or to predict the further progress of a metabolic disease in an individual.
  • any results obtained using such a diagnostic method or assay may also provide guidance to the clinician as to how a metabolic diseaase should be treated in an individual, e.g. which diet should be followed and/or which medication should be prescribed and/or the dosis regimen to be used.
  • the compound used will usually and preferably be an inhibitor of an amino acid sequence involved in the elongation of fatty acids, although the invention is its broadest sense is not limited thereto.
  • a compound is considered an inhibitor of one of the amino acid sequences involved in the elongation of fatty acids if, in a relevant assay such as the kinase activity assays refened to above (or a suitable modification thereof, for example using partially or fully purified protein), said compound reduces the activity of said amino acid sequence, i.e. by at least 1%, preferably at least 10%, such as by 20% or more, compared to the activity without the presence of said compound.
  • a compound is considered an inhibitor of one of the amino acid sequences involved in the elongation of fatty acids if, in a relevant assay, such as a binding assay, said compound has an IC50 value of less than 1000 ⁇ m, preferably at than 500 ⁇ m, more preferably less than 250 ⁇ M, even more preferably less than 100 ⁇ m, for example 50 ⁇ m or less, such as about 10 ⁇ m or less.
  • compounds are used that are modulators, and in particular inhibitors, of the human amino acid sequences of SEQ ID NO: 3, 5, 8, 11, 14, 17, 20, 23, 26 and 33, and/or of amino acid sequences derived therefrom, such as analogs, mutants, parts, fragments and/or fusions as described above.
  • the compounds of the invention may be used as a free acid or base, and/or in the form of a pharmaceutically acceptable acid-addition and/or base-addition salt (e.g. obtained with non-toxic organic or inorganic acid or base), in the form of a hydrate, solvate and/or complex, and/or in the form or a pre-drug, such as an ester.
  • the compounds of the inventions may be formulated as a pharmaceutical preparation comprising at least one compound of the invention and at least one pharmaceutically acceptable carrier, diluent or excipient and/or adjuvant, and optionally one or more further pharmaceutically active compounds.
  • such a formulation may be in a form suitable for oral administration, for parenteral administration (such as by intravenous, intramuscular or subcutaneous injection or intravenous infusion), for topical administration, for administration by inhalation, by a skin patch, by an implant, by a suppository, etc..
  • parenteral administration such as by intravenous, intramuscular or subcutaneous injection or intravenous infusion
  • topical administration for administration by inhalation, by a skin patch, by an implant, by a suppository, etc.
  • suitable administration forms - which may be solid, semi-solid or liquid, depending on the manner of administration - as well as methods and earners for use in the preparation thereof, will be clear to the skilled person; reference is again made to for instance US-A- 6,372,778, US-A-3,696, 086 and US-6,369,067.
  • the pharmaceutical preparations of the invention are preferably in a unit dosage form, and may be suitably packaged, for example in a box, blister, vial, bottle, sachet, ampoule or in any other suitable holder or container (which may be properly labeled); optionally with one or more leaflets containing product information and/or instructions for use.
  • unit dosages will contain between 1 and 500 mg of the at least one compound of the invention, e.g. about 10, 25, 50, 100, 200, 500 or 1000 mg per unit dosage.
  • at least one compound of the invention will generally be administered in an amount of between 0.01 to 150 mg/kg body weight per day of the patient, divided over one or more daily doses.
  • the invention relates to a composition, and in particular a composition for pharmaceutical use, that contains at least one compound of the invention (i.e. a compound that has been identified, discovered and/or developed using a nematode or method as described herein) and at least one suitable canier (i.e. a carrier suitable for pharmaceutical use).
  • a compound of the invention i.e. a compound that has been identified, discovered and/or developed using a nematode or method as described herein
  • suitable canier i.e. a carrier suitable for pharmaceutical use.
  • the invention also relates to the use of a compound of the invention in the preparation of such a composition.
  • the compounds and compositions of the invention are administered orally and/or in a form intended and/or suitable for oral administration.
  • the above compounds and compositions may be of value in the veterinary field, which for the purposes herein not only includes the prevention and/or treatment of diseases in animals, but also - for economically important animals such as cattle, pigs, sheep, chicken, fish, etc. - enhancing the growth and/or weight of the animal and/or the amount and/or the quality of the meat or other products obtained from the animal.
  • the invention relates to a composition for veterinary use that contains at least one compound of the invention (i.e.
  • the invention also relates to the use of a compound of the invention in the preparation of such a composition.
  • the invention may be used to identify compounds suitable for use in pesticides, insecticides, nematicides and/or other biocides or plant protection agents.
  • the compounds invention may be used to control the species listed in US-A-6,372,774.
  • the compounds of the invention may be suitably formulated with one or more agrochemically acceptable caniers, to provide a formulation suitable for agrochemical use, as will be clear to the skilled person (reference is for example made to the formulations and uses described in US-A-6,372,774).
  • the invention relates to a composition for agrochemical use that contains at least one compound of the invention (i.e. a compound that has been identified, discovered and/or developed using a nematode or method as described herein) and at least one suitable carrier (i.e. a carrier suitable for agrochemical use).
  • Figure 1 schematically shows vector pGN49A (see also WO 00/01846 and UK patent application no. GB 0012233, both by Applicant);
  • Figures 2A and 2B are photographs (enhanced using the Scion Image (Scion Corp) software package) showing reduced fat-absorption phenotype in C. elegans upon Nile Red Staining:
  • Figure 2A reduced fat storage (invention);
  • Figure 2B reference (reference vector gGN29 without RNAi insert).
  • Example 1 Preparation E.coli RNA feeding strain for expression of C56G2.6 double stranded RNA.
  • a vector for expression of dsRNA for downregulation of C. elegans gene C56G2.6 was prepared as follows. The DNA fragment of SEQ ID NO: 30, which conesponds to 821 nucleotides of the C. elegans C56G2.6 gene (SEQ ID NO.27), was obtained by PCR from genomic C. elegans DNA, using the following primers:
  • This fragment was inserted in the Sr ⁇ -site of expression vector pGN49a pGN49A ( Figure 1, see also WO 00/01846 and UK patent application no. GB 0012233, both by Applicant).
  • This vector contains two T7 promoters flanking the Sr ⁇ -site, allowing transcription of a nucleotide sequence inserted into said Sr ⁇ -site into double stranded RNA, upon binding of a T7 polymerase to said promoter (vide WO 00/01846).
  • the resulting vector, designated pGN49A- C56G2.6 was transformed overnight into E. coli strain AB 309-105 (see EP-A-1 093 526 by applicant, page 17.).
  • Example 2 Generation of fat storage phenotype in C. elegans - P0 screen for C. elesans gene C56G2.6.
  • C. elegans strain CB1370 containing the temperature sensitive daf-2 allele e-1370 is used (Ogg et al., supra).
  • CB 1370 is publicly available from, for example, the Caenorhabditis Genetics Center (CGC), Minnesota, USA).
  • Ll worms of strain CB 1370 were cultivated at a temperature of 15 °C in S-Complete fed-medium in the wells of a 96 well plate (40 Ll nematodes per well) under essentially synchronized conditions, until the nematodes reached the L2 stage. Then, the temperature was increased to 25°C, and the worms were further cultivated at said temperature until they reached the L4 stage (about 36-48 hours). Due to the presence of the daf-2 allele e-1370, this raise in temperature from 15°C to 25 °C causes the nematodes to accumulate fat, mainly in their intestinal and hypodermal tissue (vide Ogg et al. and Figures 2 A and 2B). The accumulation of fat (in the form of droplets) was made visible by means of
  • Nile Red staining L4 animals were washed several times with M9 (supplemented with 0.1%) PEG) to remove the remaining E.coli, and fixed with MeOH (fc. 33%>). After fixation the nematodes were stained with nile red (fc 0.375 mM in 37.5% MeOH) for 4 hours. MeOH and excess dye was removed through several washes with M9 (supplemented with 0.1 %> PEG). The staining pattern was visualized under UV using a 500 nm long pass filter.
  • the daf-2 (el 370) nematodes were grown in a similar manner, but with E. coli strain AB 309-105 containing vector pGN49A without the RNAi fragment for C56G2.6 inserted therein as a food source, used in the same amount. All samples were carried out in quadruplicate.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des procédés destinés à identifier et/ou à développer des composés pouvant être utilisés en vue de prévenir et/ou de traiter des maladies métaboliques, ainsi que l'utilisation de séquences d'acides aminés impliquées dans l'élongation d'acides gras dans ce type de procédés. L'invention concerne également des composés ayant été identifiés et/ou développés au moyen de ces procédés, des compositions pharmaceutiques contenant ces composés, et l'utilisation de ces composés dans la préparation de compositions pharmaceutiques, notamment des compositions pharmaceutiques destinées à prévenir et/ou à traiter des maladies métaboliques. L'invention concerne enfin des composés pouvant interagir avec les séquences d'acides aminés impliquées dans l'élongation d'acides gras, des compositions pharmaceutiques contenant ces composés et l'utilisation de ces composés dans la préparation de compositions pharmaceutiques, notamment des compositions pharmaceutiques destinées à prévenir et/ou à traiter des maladies métaboliques.
PCT/GB2004/004103 2003-09-25 2004-09-24 Utilisation de sequences d'acides amines impliquees dans l'elongation d'acides gras lors de l'identification et/ou du developpement de composes destines a prevenir et/ou a traiter des maladies metaboliques WO2005030985A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50597003P 2003-09-25 2003-09-25
US60/505,970 2003-09-25
GB0322493A GB0322493D0 (en) 2003-09-25 2003-09-25 Use of amino acid sequences involved in the elongation of fatty acids in identifying and/or developing compounds for preventing and/or treating metabolic dise
GB0322493.8 2003-09-25

Publications (2)

Publication Number Publication Date
WO2005030985A2 true WO2005030985A2 (fr) 2005-04-07
WO2005030985A3 WO2005030985A3 (fr) 2005-11-17

Family

ID=34395445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004103 WO2005030985A2 (fr) 2003-09-25 2004-09-24 Utilisation de sequences d'acides amines impliquees dans l'elongation d'acides gras lors de l'identification et/ou du developpement de composes destines a prevenir et/ou a traiter des maladies metaboliques

Country Status (1)

Country Link
WO (1) WO2005030985A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1657311A1 (fr) * 2003-07-11 2006-05-17 Banyu Pharmaceutical Co., Ltd. Methode d'evaluation de compose efficace dans le traitement de l'obesite
WO2008009858A2 (fr) * 2006-07-19 2008-01-24 Galderma Research & Development Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée
WO2019240946A1 (fr) * 2018-06-11 2019-12-19 The Regents Of The University Of California Déméthylation pour traiter une maladie oculaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076308A1 (fr) * 1999-06-14 2000-12-21 Exelixis, Inc. Modeles animaux et methodes d'analyse du metabolisme des lipides et criblage d'agents pharmaceutiques et de pesticides modulant le metabolisme des lipides
WO2002062974A2 (fr) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation de la proteine humaine elongase hselo1
WO2003019146A2 (fr) * 2001-08-29 2003-03-06 Xenon Genetics Inc. Essais de criblage a haut rendement mettant en oeuvre des enzymes synthetiques d'acide gras

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076308A1 (fr) * 1999-06-14 2000-12-21 Exelixis, Inc. Modeles animaux et methodes d'analyse du metabolisme des lipides et criblage d'agents pharmaceutiques et de pesticides modulant le metabolisme des lipides
WO2002062974A2 (fr) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation de la proteine humaine elongase hselo1
WO2003019146A2 (fr) * 2001-08-29 2003-03-06 Xenon Genetics Inc. Essais de criblage a haut rendement mettant en oeuvre des enzymes synthetiques d'acide gras

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOON Y-A ET AL: "Identification of a Mammalian Long Chain Fatty Acyl Elongase Regulated by Sterol Regulatory Element-binding Proteins" JOURNAL OF BIOLOGICAL CHEMISTRY 30 NOV 2001 UNITED STATES, vol. 276, no. 48, 30 November 2001 (2001-11-30), pages 45358-45366, XP002963525 ISSN: 0021-9258 *
MOON YOUNG-AH ET AL: "Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 9, 28 February 2003 (2003-02-28), pages 7335-7343, XP002316434 ISSN: 0021-9258 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1657311A1 (fr) * 2003-07-11 2006-05-17 Banyu Pharmaceutical Co., Ltd. Methode d'evaluation de compose efficace dans le traitement de l'obesite
EP1657311A4 (fr) * 2003-07-11 2006-10-11 Banyu Pharma Co Ltd Methode d'evaluation de compose efficace dans le traitement de l'obesite
US7491381B2 (en) 2003-07-11 2009-02-17 Banyu Pharmaceutical Co., Ltd. Method of evaluating compound efficacious in treating obesity
WO2008009858A2 (fr) * 2006-07-19 2008-01-24 Galderma Research & Development Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée
FR2903998A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de elovl5 dans le traitement de l'acne ou de l'hyperseborrhee
WO2008009858A3 (fr) * 2006-07-19 2008-05-08 Galderma Res & Dev Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée
WO2019240946A1 (fr) * 2018-06-11 2019-12-19 The Regents Of The University Of California Déméthylation pour traiter une maladie oculaire
US10632211B2 (en) 2018-06-11 2020-04-28 The Regents Of The University Of California Demethylation to treat eye disease

Also Published As

Publication number Publication date
WO2005030985A3 (fr) 2005-11-17

Similar Documents

Publication Publication Date Title
Weiss et al. Species-specific differences in expression of G-protein-coupled receptor kinase (GRK) 7 and GRK1 in mammalian cone photoreceptor cells: implications for cone cell phototransduction
Meili et al. Chemoattractant‐mediated transient activation and membrane localization of Akt/PKB is required for efficient chemotaxis to cAMP in Dictyostelium
Ramakrishnan et al. Apicoplast and endoplasmic reticulum cooperate in fatty acid biosynthesis in apicomplexan parasite Toxoplasma gondii
Williams et al. Trio’s Rho-specific GEF domain is the missing Gαq effector in C. elegans
Leon et al. Identification of TER94, an AAA ATPase protein, as a Bam-dependent component of the Drosophila fusome
Cockcroft et al. Biochemical and biological functions of class I phosphatidylinositol transfer proteins
Jones et al. Conservation of estrogen receptor function in invertebrate reproduction
JP5940541B2 (ja) Ｇｐｃｒ ｇａｌｒ２の調節剤としてのニューロペプチドｑ及びその使用
JP4990789B2 (ja) Ｇｐｒ４０とホスホリパーゼとを用いる疾患に有用な物質のスクリーニング方法
Zhao et al. An RDH‐Plin2 axis modulates lipid droplet size by antagonizing Bmm lipase
WO2005030985A2 (fr) Utilisation de sequences d'acides amines impliquees dans l'elongation d'acides gras lors de l'identification et/ou du developpement de composes destines a prevenir et/ou a traiter des maladies metaboliques
Fritzler et al. Cryptosporidium parvum long-chain fatty acid elongase
Liu et al. Fat body-specific reduction of CTPS alleviates HFD-induced obesity
CN108138239A (zh) 用于确定衰老、确定肥胖症和诊断癌症的生物标志物和使用其的诊断试剂盒
Gao et al. Molecular cloning and DNA binding characterization of DAF-16 orthologs from Ancylostoma hookworms
US20070092910A1 (en) Alcohol dehydrogenase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases
Schröder et al. Synthesis of the neurotoxin quinolinic acid in apoptotic tissue from Suberites domuncula: Cell biological, molecular biological, and chemical analyses
US20060275767A1 (en) Kinase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases and nucleotide sequences encoding such kinase sequences
Elliot Murphy et al. In vitro reconstitution of substrate S-acylation by the zDHHC family of protein acyltransferases
Kotani et al. Mys Protein Regulates Protein Kinase A Activity by Interacting with Regulatory Type Iα Subunit during Vertebrate Development 2
EP3476403A1 (fr) Procédé de régulation de la lipolyse et du métabolisme oxydatif des acides gras
JP4674332B2 (ja) Ｔｘｋ複合体およびその利用
Duncan et al. Enzymes of energy metabolism in hatchlings of amazonian freshwater turtles (Testudines, Podocnemididae)
EP1597361A2 (fr) Sequences de kinases utilisees dans la mise au point de composes destines a prevenir et/ou a traiter des maladies metaboliques, et sequences nucleotidiques codant pour lesdites sequences de kinases
WO2008098995A2 (fr) Gènes mis en jeu dans la biogenèse mitochondriale

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase